AB Science reports operating deficit but positive updates on masitinib and AB8939 programs

From GlobeNewswire: 2025-05-12 02:14:00

AB Science reports a 6.1 million euro operating deficit and 8.0 million euros in cash as of December 31, 2024. Key events include updates on masitinib for multiple sclerosis, Covid-19, and neurodegenerative diseases. The company is strengthening intellectual property for masitinib in mastocytosis and sickle cell disease, and the AB8939 microtubule program.

AB Science updates on the AB8939 microtubule program, showing potential to treat relapsed/refractory acute myeloid leukemia. The Phase 1 study aims to determine the maximum tolerated dose and combination with other drugs. AB8939 targets the MECOM gene, associated with poor prognosis, and shows a 50% response rate in early data.

Masitinib shows promise in treating progressive forms of multiple sclerosis, reducing EDSS progression and improving manual dexterity. The drug targets microglia and mast cells, with a large safety database. Results from a Phase 2 study in Covid-19 are positive, suggesting masitinib as a potential new treatment option.



Read more at GlobeNewswire:: AB Science reports its revenues for the year 2024 and